ARTICLE | Clinical News

Xifaxan rifaximin: Additional Phase III data

March 29, 2010 7:00 AM UTC

Additional data from the double-blind, international Phase III RFHE3001 trial in 299 patients showed that 550 mg twice-daily oral Xifaxan for 6 months significantly reduced the risk of HE-related hospitalization by 50% compared with placebo (13.6% vs. 22.6%, p=0.0129). Data were published in the New England Journal of Medicine. Salix previously reported that Xifaxan significantly prevented recurrence of HE by 58% vs. placebo (see BioCentury, May 4, 2009). ...